Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
HCV Advocate

Thursday, April 18, 2013

Tenofovir/emtricitabine topped other regimens for patients coinfected with HIV, HBV

Combining tenofovir disoproxil fumarate with emtricitabine resulted in greater long-term hepatitis B virus suppression than other treatments among patients coinfected with HIV and HBV in a recent study.
In a multinational longitudinal study, researchers collected data from 165 HIV/HBV-coinfected patients from the United States, Australia and Thailand. The majority of the cohort (90.3%) either used or planned to use highly active antiretroviral therapy (HAART) within 1 year of study initiation. Patient follow-up occurred every 6 months for a median of 2.8 years, resulting in 1,015 study visits. Using logistic regression, researchers determined factors associated with detectable HBV DNA (characterized as greater than 357 IU/mL).


No comments:

Post a Comment